Omeprazole liquid otc
Pro Research Analysisby 
Searched over 200M research papers
Omeprazole Liquid OTC: Development and Efficacy
Introduction to Omeprazole OTC for Heartburn Relief
Omeprazole is a widely used medication for the treatment of conditions caused by excess stomach acid, such as frequent heartburn. Over-the-counter (OTC) formulations of omeprazole, such as Prilosec OTC™, have been developed to provide consumers with accessible and effective relief from these conditions. Studies have shown that omeprazole magnesium, in doses of 10.3 mg and 20.6 mg, is effective in treating frequent heartburn over a 14-day regimen1.
Development of Liquid Omeprazole Formulations
Pediatric and Swallowing Impairment Considerations
One significant challenge in the administration of omeprazole is its availability primarily in solid forms, such as tablets and capsules. This poses difficulties for pediatric patients and individuals with swallowing impairments. To address this, researchers have developed liquid formulations of omeprazole, including nanoparticle suspensions and delayed-release liquid oral dosage forms.
Omeprazole Nanoparticles Suspension
A study focused on creating a stable liquid formulation of omeprazole using nanoparticles aimed at pediatric administration. The formulation utilized Eudragit® RS100 and Eudragit® L100-55 to create a pH-sensitive coating, ensuring the stability and effectiveness of the drug. The nanoparticles demonstrated significant protective effects against ulcer formation in mice, indicating their potential as a therapeutic strategy in a liquid form suitable for children2.
Delayed-Release Liquid Oral Dosage Form
Another innovative approach involved the development of a delayed-release liquid oral dosage form of omeprazole. This formulation used multi-layered particles suspended in a syrup, designed to release the drug in a controlled manner. The coating with Eudragit® E100 and Eudragit® L100-55 ensured the stability of omeprazole in acidic environments and targeted its release in the intestines. This technology showed similar release performance to existing enteric-coated solid dosage forms and provided a viable option for patients with swallowing difficulties3.
Conclusion
The development of liquid formulations of omeprazole, including nanoparticle suspensions and delayed-release syrups, represents a significant advancement in making this medication more accessible to pediatric patients and those with swallowing impairments. These innovations ensure the stability and effectiveness of omeprazole, providing a promising alternative to traditional solid dosage forms. As research continues, these liquid formulations may become more widely available, offering improved compliance and therapeutic outcomes for a broader range of patients.
Sources and full results
Most relevant research papers on this topic
Comparison of Prilosec OTCTM (omeprazole magnesium 20·6 mg) to placebo for 14 days in the treatment of frequent heartburn
Prilosec OTC (omeprazole magnesium 20-6 mg) is a safe and effective over-the-counter treatment for frequent heartburn when administered as a 14-day regimen.
RCTOmeprazole nanoparticles suspension: development of a stable liquid formulation with a view to pediatric administration.
Omeprazole nanoparticles suspension effectively protects mice stomachs against ulcer formation, offering a potential pediatric-friendly liquid pharmaceutical form for treating gastric hypersecretion disorders.
Non-RCT
Animal StudyDevelopment and evaluation of an omeprazole-based delayed-release liquid oral dosage form.
Our new technology developed for omeprazole-based delayed-release liquid oral dosage forms offers similar release performance to existing enteric dosage forms, enhancing patient compliance in swallowing impairments.
Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn.
Consumers accurately self-select for OTC omeprazole, follow a 14-day regimen, and seek physician involvement for longer-term management of frequent heartburn.
Observational StudyStability of omeprazole in an extemporaneously prepared oral liquid.
Omeprazole 2 mg/mL in an oral liquid compounded from capsules and sodium bicarbonate injection is stable for up to 14 days at 24 degrees C and up to 30 days at 5 and -20 degrees C.
Omeprazole nanoparticles suspension: Development of a stable liquid formulation with a view to pediatric administration
Omeprazole nanoparticles suspension effectively protects mice stomachs from ulcer formation, offering a potential pediatric-friendly liquid pharmaceutical form for treating gastric hypersecretion disorders.
Non-RCTAnimal StudyStability of Omeprazole Extemporaneous Oral Solution in Chopin Base.
The extemporaneous liquid formulation of omeprazole in Chopin base is stable and suitable for all patients, particularly those unable to take other pharmaceutical dosage forms.
[Efficacy and safety of OTC omeprazole].
OTC omeprazole provides fast and long-lasting symptom relief for heartburn and acid regurgitation, with high satisfaction and low adverse events.
Observational StudyDevelopment of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology.
Nanosuspension technology using DissoCubes technology successfully creates a stable, highly concentrated omeprazole formulation for intravenous injection, preventing degradation of labile drugs.
Highly CitedSimultaneous determination of omeprazole and its metabolites in plasma and urine by reversed-phase high-performance liquid chromatography with an alkaline-resistant polymer-coated C18 column.
The developed reversed-phase high-performance liquid chromatographic method accurately determines omeprazole and its metabolites in plasma and urine, aiding in understanding its kinetic disposition and metabolism in the human liver.
Highly Cited